NCT03384940 - DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

August 9, 2019

Study Completion Date

November 10, 2020

Conditions

Colorectal Neoplasm

Interventions

DRUG

DS-8201a

DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration

Trial Locations (25)

20133

Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

31008

Clinica Universidad de Navarra, Pamplona

35128

Oncology Institute Veneto IOV-IRCCS, Padua

37232

Vanderbilt University Medical Center, Nashville

38138

West Cancer Center, Germantown

48201

Karmanos Cancer Institute, Detroit

80131

Università degli studi della Campania L.Vanvitelli, Napoli

90089

University of Southern California, Los Angeles

90404

UCLA Health, Santa Monica

91010

City of Hope Medical Center, Duarte

32224-1865

Mayo Clinic Jacksonville, Jacksonville

29605-4255

Greenville Health System Cancer Institute, Greenville

77030-4000

MD Anderson Cancer Center, University of Texas, Houston

464-8681

Aichi Cancer Center Hospital, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa

791-0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

060-8648

Hokkaido University Hospital, Sapporo

589-8511

Kindai University Hospital, Ōsaka-sayama

135-8550

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Universitari Clinic de Barcelona, Barcelona

SM2 5PT

Royal Marsden Institute (Chelsea), Chelsea

SW3 6JJ

Royal Marsden Institute (Sutton), Sutton